



Chikungunya Virus

IgM μ -capture ELISA

Enzyme immunoassay for the qualitative determination of IgM-class antibodies against Chikungunya virus in human serum or plasma

For laboratory use only.

Product Number: NB-06-0272 (96 Determinations)

1. INTRODUCTION

Chikungunya virus is an arthropod borne virus of the genus Alphavirus (family Togaviridae). The Alphavirus genus contains at least 24 distinct species. These are lipid-enveloped virions with a diameter of 50 to 60 nm.

Alphavirus infections are initiated by the bite of an infected mosquito, which results in the deposition of virus in subcutaneous and possibly cutaneous tissues. After an incubation period of 1 to 12 days the Chikungunya fever develops.

Chikungunya fever (Chikungunya means “that which bends up”, in reference to the crippling manifestations of the disease) is an acute viral infection characterized by a rapid transition from a state of good health to illness that includes severe arthralgia and fever.

Temperature rises abruptly to as high as 40°C and is often accompanied by shaking chills. After a few days, fever may abate and recrudescence, giving rise to a “saddleback” fever curve. Arthralgia is polyarticular, favoring the small joints and sites of previous injuries, and is most intense on arising. Patients typically avoid movement as much as possible. Joints may swell without significant fluid accumulations. These symptoms may last from 1 week to several months and are accompanied by myalgia. The rash characteristically appears on the first day of illness, but onset may be delayed. It usually arises as a flush over the face and neck, which evolves to a maculopapular or macular form that may be pruritic. The latter lesions appear on the trunk, limbs, face, palms and soles, in that order of frequency. Petechial skin lesions have also been noted. Headache, photophobia, retro-orbital pain, sore throat with objective signs of pharyngitis, nausea and vomiting also occur in this setting. Occasionally, however persistent arthralgia and polyarthritis (lasting months or even years) do occur, sometimes involving joint destruction. Even rarer, sequelae include encephalitis and meningoencephalitis with high lethality rates.

The virus has major importance in Africa and Asia. From 20% to more than 90% of the population of tropical and subtropical show serologic evidence of infection. Because Aedes mosquitoes are increasingly prevalent in North Africa and South America, where the population would be uniformly susceptible to infection, the possibility for epidemics is evident. Chikungunya virus infections are imported to central Europe mainly by travellers to tropical and subtropical countries.

Species	Diseases	Symptoms	Mechanism of infection
Chikungunya virus (Alphavirus)	Chikungunya fever	Fever Exanthema Joint pain Persistent arthralgia and polyarthritis, sometimes involving joint destruction. Even rarer encephalitis and meningoencephalitis	Transmission by bloodsucking mosquitoes Aedes albopictus (Africa) Aedes aegypti (Africa, Asia)

The presence of virus resp. infection may be identified by

- Serology: Detection of antibodies by IF, ELISA

2. INTENDED USE

The Chikungunya IgM μ -capture ELISA is intended for the qualitative determination of IgM class antibodies to Chikungunya virus in human serum and plasma (citrate).

3. PRINCIPLE OF THE ASSAY

The qualitative immunoenzymatic determination of IgM-class antibodies to Chikungunya is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique.

Microtiter strip wells are precoated with anti human IgM to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample and control material Chikungunya antigen solution is added. After a further washing step a mixture of biotinylated Chikungunya antibody and Streptavidin conjugate is added. After washing the captured Chikungunya-specific immunocomplex is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of Chikungunya-specific IgM antibodies in the patient specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader.

4. MATERIALS

4.1. Reagents supplied

- **Chikungunya Microplate (IgM):** 12 breakapart 8-well snap-off strips coated with anti human IgM, in resealable aluminium foil.
- **Sample Diluent ***:** 1 bottle containing 100 ml of ready to use buffer for sample dilution; pH 7.2 \pm 0.2; coloured yellow; white cap.
- **Stop Solution:** 1 bottle containing 15 ml. Ready to use sulphuric acid, 0.2 mol/l; red cap.
- **Washing Solution (20x conc.):** 1 bottle each containing 50 ml of a 20-fold concentrated buffer (pH 7.2 \pm 0.2) for washing the wells; white cap.
- **Chikungunya antigen, lyophilised:** 6 bottles containing lyophilized Chikungunya antigen solution; red cap

- **Chikungunya antibody Solution****:** 1 bottle containing 6 ml of biotinylated Chikungunya antibody, ready to use; coloured blue; white cap
- **Streptavidin conjugate**:** 1 bottle containing 6 ml Streptavidin conjugated with peroxidase, ready to use; coloured red, black cap
- **TMB Substrate Solution:** 1 bottle containing 15 ml 3,3',5,5'-tetramethylbenzidine (TMB); ready to use; yellow cap.
- **Chikungunya IgM Positive Control****:** 1 bottle containing 1.5 ml; coloured yellow; ready to use; red cap.
- **Chikungunya IgM Cut-off Control****:** 1 bottle containing 2 ml; coloured yellow; ready to use; green cap.
- **Chikungunya IgM Negative Control****:** 1 bottle containing 1.5 ml; coloured yellow; ready to use; blue cap.

* contains 0.1 % Bronidox L after dilution

** contains 0.2 % Bronidox L

*** contains 0.1 % Kathon

**** contains 0.02 % Kathon and 0.02% Bronidox L after reconstitution

4.2. Materials supplied

- 1 Strip holder
- 1 Cover foils
- 1 Test protocol
- 1 distribution and identification plan

4.3. Materials and Equipment needed

- ELISA microwell plate reader, equipped for the measurement of absorbance at 450/620nm
- Incubator 37°C
- Manual or automatic equipment for rinsing wells
- Pipettes to deliver volumes between 10 and 1000 µl
- Vortex tube mixer
- Deionised or (freshly) distilled water
- Disposable tubes
- Timer

5. STABILITY AND STORAGE

The reagents are stable up to the expiry date stated on the label when stored at 2...8 °C.

6. REAGENT PREPARATION

It is very important to bring all reagents, samples and controls to room temperature (20...25°C) before starting the test run!

6.1. Microplate

The ready to use breakapart snap-off strips are coated with anti human IgM. Store at 2...8°C. *Immediately after removal of strips, the remaining strips should be resealed in the aluminium foil along with the desiccant supplied and stored at 2...8 °C; stability until expiry date.*

6.2. Chikungunya Antigen

The bottles contain lyophilized Chikungunya antigen solution. The content of each vial has to be resolved in 1 ml diluted washing solution by turning it slowly (no vortex) and 15 min incubation at room temperature. The reconstituted solution is at 2...8°C stable for 1 days.

6.3. Chikungunya Antibody Solution

The bottle contains 6 ml biotinylated Chikungunya antibody, stabilizers, preservatives and an inert blue dye. This ready to use solution has to be stored at 2...8°C. *After first opening stability expiry date when stored at 2...8°C.*

6.4. Controls

The bottles labelled with Positive, Cut-off and Negative Control contain a ready to use control solution. They have to be stored at 2...8°C. *After first opening stability until expiry date when stored at 2...8°C.*

6.5. Washing solution (20xconc.)

The bottle contains 50 ml of a concentrated buffer, detergents and preservatives. Dilute Washing Solution 1+19; e.g. 10 ml Washing Solution + 190 ml fresh and germ free redistilled water. The diluted buffer is stable for 5 days at room temperature. *After first opening the concentrate is stable until expiry date when stored at 2...8°C.*

6.6. Sample Diluent

The bottle contains 100 ml sample dilution buffer, detergents and preservatives. It is used for the dilution of the patient specimen. *After first opening the buffer solution is stable until expiry date when stored at 2...8°C.*

6.7. Streptavidin Conjugate

1 bottle contains 6 ml Streptavidin conjugated with peroxidase, detergents and preservatives, coloured red. The reagent is ready to use and has to be stored at 2...8°C. *After first opening the conjugate is stable until expiry date when stored at 2...8 °C.*

6.8. TMB Substrate Solution

The bottle contains 15 ml of a tetramethylbenzidine/hydrogen peroxide system. The reagent is ready to use and has to be stored at 2...8°C, away from the light. *The solution should be colourless or could have a slight blue tinge. If the substrate turns into blue, it may have become contaminated and should be thrown away. After first opening stability expiry date when stored at 2...8°C.*

6.9. Stop Solution

The bottle contains 15 ml 0.2 M sulphuric acid solution (R 36/38, S 26). This ready to use solution has to be stored at 2...8°C. *After first opening stability until expiry date.*

7. SPECIMEN COLLECTION AND PREPARATION

Use human serum or plasma (citrate) samples with this assay. If the assay is performed within 5 days after sample collection, the specimen should be kept at 2...8°C; otherwise they should be aliquoted and stored deep-frozen (-20 to -70°C). If samples are stored frozen, mix thawed samples well before testing. *Avoid repeated freezing and thawing.* Heat inactivation of samples is not recommended.

7.1. Sample Dilution

Before assaying, all samples should be diluted 1+100 with IgM Sample Diluent. Dispense 10µl sample and 1ml IgM Sample Diluent into tubes to obtain a 1+100 dilution and thoroughly mix with a Vortex.

8. ASSAY PROCEDURE

8.1. Test Preparation

Please read the test protocol carefully **before** performing the assay. Result reliability depends on strict adherence to the test protocol as described. If performing the test on ELISA automatic systems we recommend to increase the washing steps from three to five and the volume of washing solution from 300µl to 350µl to avoid washing effects. Prior to commencing the assay, the distribution and identification plan for all specimens and controls should be carefully established on the result sheet supplied in the kit. Select the required number of microtiter strips or wells and insert them into the holder.

Please allocate at least:

1 well	(e.g. A1)	for the substrate blank,
1 well	(e.g. B1)	for the negative control,
2 wells	(e.g. C1+D1)	for the cut-off control and
1 well	(e.g. E1)	for the positive control.

It is left to the user to determine controls and patient samples in duplicate, if necessary.

Perform all assay steps in the order given and without any appreciable delays between the steps.

A clean, disposable tip should be used for dispensing each control and sample.

Adjust the incubator to 37° ± 1°C.

1. Dispense 50µl controls and diluted samples into their respective wells. Leave well A1 for substrate blank.
2. Cover wells with the foil supplied in the kit.
3. **Incubate for 1 hour ± 5 min at 37±1°C.**
4. When incubation has been completed, remove the foil, aspirate the content of the wells and wash each well three times with 300µl of washing solution. Avoid overflows from the reaction wells. The soak time between each wash cycle should be >5sec. At the end carefully remove remaining fluid by tapping strips on tissue paper prior to the next step!

Note: Washing is critical! Insufficient washing results in poor precision and falsely elevated absorbance values.

5. Dispense 50µl Chikungunya antigen into all wells except for the blank well (e.g. A1). Cover with foil.
6. **Incubate for 30 min at room temperature.**
7. Repeat step 4.
8. Dispense 50 µl Chikungunya Antibody Solution into all wells except for the blank well (e.g.A1). Cover with foil.
9. **Incubate for 30 min at room temperature.**

10. Repeat step 4.
11. Dispense 50 µl Streptavidin peroxidase conjugate into all wells except for the blank (e.g. A1). Cover with foil.
12. **Incubate for 30 min at room temperature.**
13. Repeat step 4.
14. Dispense 100 µl TMB solution into all wells
15. **Incubate for exact 15 min. in the dark.**
16. Dispense 100µl Stop Solution into all wells in the same order and at the same rate as for the TMB substrate.
Any blue colour developed during the incubation turns into yellow.
Note: Highly positive patient samples can cause dark precipitates of the chromogen! These precipitates have an influence when reading the optical density. Predilution of the sample with negative matrix for example 1+1, is recommended. Then dilute the sample 1+100 with dilution buffer and multiply the results in NTU by 2.
17. Measure the absorbance of the specimen at 450/620nm within 30 min after addition of the Stop Solution.

8.2. Measurement

Adjust the ELISA Microwell Plate Reader **to zero** using the **substrate blank in well A1**.

If - due to technical reasons - the ELISA reader cannot be adjusted to zero using the substrate blank in well A1, subtract the absorbance value of well A1 from all other absorbance values measured in order to obtain reliable results!

Measure the absorbance of all wells at **450 nm** and record the absorbance values for each control and patient sample in the distribution and identification plan.

Dual wavelength reading using 620 nm as reference wavelength is recommended.

Where applicable calculate the **mean absorbance values** of all duplicates.

9. RESULTS

9.1. Assay Validation Criteria

In order for an assay to be considered valid, the following criteria must be met:

- **Substrate blank** in A1: Absorbance value < **0.100**
- **Negative control** in B1: Absorbance value < **cut-off**
- **Cut-off control** in C1 and D1: Absorbance value **0.150 - 1.300**
- **Positive control** in E1: Absorbance value > cut-off

If these criteria are not met, the test is not valid and must be repeated.

9.2. Calculation of Results

The cut-off is the mean absorbance value of the Cut-off control determinations.

Example: Absorbance value Cut-off control 0.39 + absorbance value Cut-off control 0.37 = 0.76 / 2 = 0.38

$$\text{Cut-off} = 0.38$$

9.3. Interpretation of Results

Samples are considered **POSITIVE** if the absorbance value is higher than 10% over the cut-off.

Samples with an absorbance value of 10% above or below the cut-off should not be considered as clearly positive or negative
→ **grey zone**

It is recommended to repeat the test again 2 - 4 weeks later with a fresh sample. If results in the second test are again in the grey zone the sample has to be considered **NEGATIVE**.

Samples are considered **NEGATIVE** if the absorbance value is lower than 10% below the cut-off.

9.3.1. Results in NeoBiotech Units

$$\frac{\text{Patient (mean) absorbance value} \times 10}{\text{Cut-off}} = [\text{NeoBiotech-Units} = \text{NTU}]$$

Example: $\frac{1.216 \times 10}{0.38} = 32 \text{ NTU}$

Cut-off:	10	NTU
Grey zone:	9-11	NTU
Negative:	<9	NTU

Positive: >11 NTU

10. SPECIFIC PERFORMANCE CHARACTERISTICS

10.1. Precision

Intraassay	n	Mean value (OD)	CV (%)
Low positive serum	23	0.62	4.8
Positive serum	24	1,36	3.4

Interassay	n	Mean value (OD)	CV (%)
Low positive serum	3 (69)	0.61	7.3
Positive serum	3 (72)	1.36	2.9

10.2. Diagnostic Specificity

The diagnostic specificity is defined as the probability of the assay of scoring negative in the absence of the specific analyte. negative samples have been tested. The diagnostic specificity is > 90%.

10.3. Diagnostic Sensitivity

The diagnostic sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analyte. positive samples have been tested. The diagnostic sensitivity is >90%.

10.4. Interferences

No interferences were observed when adding triglycerides, bilirubin and haemoglobin in an excess to the sample.

10.5. Cross reactivity

No cross reactivity were observed by using Rf-samples and samples containing antibodies against Bordetella pertussis, Chlamydia trachomatis, Chlamydia pneumoniae, Dengue Virus, TBE, Helicobacter pylori, HSV 2, Leishmania, Mycoplasma and Schistosoma.

Cross reactivity with antibodies against Borrelia, CMV and Toxoplasma cannot be excluded.

Interference with polyclonal stimulation of EBV infections is likely. In the presence of infectious Mononucleosis (Pfeiffer´s Disease, EBV infection) polyclonal stimulation of B lymphocytes can occur. This may result in non-specific reactions in the detection of antibodies of the IgM class. Therefore it is recommended to exclude an EBV infection by differential diagnosis.

Cross reactivity with antibodies against other alphaviruses cannot be excluded.

Note: The results refer to the groups of samples investigated; these are not guaranteed specifications.

11. LIMITATIONS OF THE PROCEDURE

Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values. Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data.

In immunosupremized patients and newborns serological data only have restricted value.

12. PRECAUTIONS AND WARNINGS

- In compliance with article 1 paragraph 2b European directive 98/79/EC the use of the in vitro diagnostic medical devices is intended by the manufacturer to secure suitability, performances and safety of the product. Therefore the test procedure, the information, the precautions and warnings in the instructions for use have to be strictly followed. The use of the test kits with analyzers and similar equipment has to be validated. Any change in design, composition and test procedure as well as for any use in combination with other products not approved by the manufacturer is not authorized; the user himself is responsible for such changes. The manufacturer is not liable for false results and incidents for these reasons. The manufacturer is not liable for any results by visual analysis of the patient samples.
- Only for in-vitro diagnostic use.
- All components of human origin used for the production of these reagents have been tested for anti-HIV antibodies, anti-HCV antibodies and HBsAg and have been found to be non-reactive. Nevertheless, all materials should still be regarded and handled as potentially infectious. Wear gloves while performing the test
- **The Chikungunya antigens (Solution 1) are inactivated. All materials should still be regarded and handled as potentially infectious. Wear gloves while performing the test. We recommend using Solution 1 under BSL2 cabinet (clean bench).**
- Do not interchange reagents or strips of different production lots.
- No reagents of other manufacturers should be used along with reagents of this test kit.
- Do not use reagents after expiry date stated on the label.
- Use only clean pipette tips, dispensers, and lab ware.
- Do not interchange screw caps of reagent vials to avoid cross-contamination.

- Close reagent vials tightly immediately after use to avoid evaporation and microbial contamination.
- After first opening and subsequent storage check conjugate and control vials for microbial contamination prior to further use.
- To avoid cross-contamination and falsely elevated results pipette patient samples and dispense conjugate without splashing accurately to the bottom of wells.
- The NeoBiotech ELISA is only designed for qualified personnel who are familiar with good laboratory practice.

WARNING: In the used concentration Bronidox L has hardly any toxicological risk upon contact with skin and mucous membranes!

WARNING: Sulphuric acid irritates eyes and skin. Keep out of the reach of children. Upon contact with the eyes, rinse thoroughly with water and consult a doctor!

12.1. Disposal Considerations

Residues of chemicals and preparations are generally considered as hazardous waste. The disposal of this kind of waste is regulated through national and regional laws and regulations. Contact your local authorities or waste management companies which will give advice on how to dispose hazardous waste.

13. ORDERING INFORMATION

Product Number: Nb-06-0272

Chikungunya Virus IgM μ -capture ELISA (96 Determinations)

BIBLIOGRAPHY

- Gerald L. Mandell, John E. Bennett, Raphael Dolin, Principles and practice of Infectious diseases, 2005, Chapter 147, 1913–1919
- Patrick Hochedez, Staphane Jaureguierry, Monique Debruyne, Philippe Bossi, Pierre Hausfater, Gilles Brucker, Francois Bricaire, Eric Caumes, Chikungunya infection in travellers, Emerging Infectious Diseases Vol. 12, No. 10, October 2006, 1565-1566
- F.H. Kayser, K.A. Bienz, J. Eckert, R.M. Zinkernagel, Medical Microbiology, Stuttgart 2005, 440-441

SCHEME OF THE ASSAY

Chikungunya Virus IgM μ -capture -ELISA

Assay preparation

Prepare reagents and samples as described.
 Establish the distribution and identification plan for all specimens and controls on the form supplied in the kit.
 Select the required number of microtiter strips or wells and insert them into the holder.

Assay procedure

	Substrate blank (e.g. A1)	Negative control	Positive control	Cut-off control	Sample (diluted 1+100)
Negative control	-	50 μ l	-	-	-
Positive control	-	-	50 μ l	-	-
Cut-off control	-	-	-	50 μ l	-
Sample (diluted 1+100)	-	-	-	-	50 μ l
Cover wells with foil supplied in the kit Incubate for 1 h at 37°C Wash each well three times with 300 μ l of washing solution					
Solution 1	-	50 μ l	50 μ l	50 μ l	50 μ l
Cover wells with foil supplied in the kit Incubate for 30 min at room temperature Wash each well three times with 300 μ l of washing solution					
Mixture of Solution 2 /Streptavidin conjugate (1 +1)	-	50 μ l	50 μ l	50 μ l	50 μ l
Cover wells with foil supplied in the kit Incubate for 30 min at room temperature Wash each well three times with 300 μ l of washing solution					
TMB	100 μ l	100 μ l	100 μ l	100 μ l	100 μ l
Cover wells with foil supplied in the kit Incubate for exact 15 min at room temperature in the dark					
Stop solution	100 μ l	100 μ l	100 μ l	100 μ l	100 μ l
Photometric measurement at 450 nm (reference wavelength: 620 nm)					